Delivering RNAi therapeutics

MDRNA is developing a diverse pre-clinical pipeline of therapeutics based on novel approaches utilizing proprietary RNAi technologies and delivery systems. First among these are the following development programs:

• Oncology
• Metabolic disorders
• Inflammation

To fuel its pipeline, MDRNA is building one of the broadest and extensive patent estates in the RNAi field, with more than 260 filed patents addressing 144 gene sequences including numerous disease-validated targets.

Therapeutic programs

Therapeutic Focus: Metabolic dysfunction
Indication: Hypercholesterolemia
Clinical Candidate: MDR-04227

Therapeutic Focus: Oncology
Indication: Bladder cancer
Clinical Candidate: MDR-09521

Therapeutic Focus: Inflammation
Indication: IBD/RA
Clinical Candidate: MDR-06155

Therapeutic Focus: Respiratory virus
Indication: Influenza
Clinical Candidate: MDR-03030

Therapeutic Focus: Oncology
Indication: Lung cancer
Clinical Candidate: MDR-09513